Posted on

Put your city on the TC map — TechCrunch’s European Cities Survey 2021

TechCrunch is embarking on a major new project to survey European founders and investors in cities outside the larger European capitals.
Over the next few weeks, we will ask entrepreneurs in these cities to talk about their ecosystems, in their own words.
This is your chance to put your city on the Techcrunch Map!
This is the follow-up to the huge survey of investors (see also below) we’ve done over the last 6 or more months, largely in capital cities.
These formed part of a broader series of surveys we’re doing regularly for ExtraCrunch, our subscription service which unpacks …

Read More

Posted on

Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too

Just three years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. Despite its youth, Immunai has already established the largest database in the world for single cell immunity characteristics, and it has already used its machine learning-powered immunity analysts platform to enhance the performance of existing immunotherapies, but aided by this new funding, it’s now ready to expand into the development of entirely new therapies based on the strength and breadth of its data and ML.
Immunai’s approach to developing new insights around the human immune …

Read More

Posted on

Bristol entrepreneur who exited for $800M doubles-down on the city with deep-tech incubator and VC fund

Harry Destecroix co-founded Ziylo while studying for his PhD at the University of Bristol. Ziylo, a university spin-out company, developed a synthetic molecule allowing glucose to bind with the bloodstream more effectively. Four years later, and by then a Phd, Destecroix sold the company to Danish firm Novo Nordisk, one of the biggest manufacturers of diabetes medicines, which had realized it could use Ziylo’s molecule to develop a new type of insulin to help diabetics. He walked away with an estimated $800m.
Destecroix is now embarking on a project, “Science Creates”, to repeat the exercise of creating deep-tech, science-based …

Read More